Pharma Report 2012: Get Back in Shape

Share this article:
Pharma Report 2012: Get Back in Shape
Pharma Report 2012: Get Back in Shape

20    Forest Laboratories    $5.2B     up 10.6%
Global revenue*: $4.2B (20th); up 7.7%

R&D spend*: $716M (19th), down 34.9%; 17.0% of rev.

Top brands: Lexapro ($2.9B), Namenda ($1.5B), Bystolic ($383M)

Planned launches: Aclidinium (COPD), ­linaclotide (IBS)

Promotional spend: $866M (9th); 17.5% of rev.

Patent expirations: Lexapro (2012), Namenda (2015)

Forest's top-selling drug, $2.9-billion SSRI Lexapro, just lost patent protection, and number two drug Namenda's next in 2015. On the other other hand, there's the boffo sideshow that is longtime chief Howard Solomon's ongoing battles with (some would say persecution by) HHS and activist investor Carl Icahn. The upside is the company launched Teflaro in March, following Daliresp and Viibryd, and has already filed NDAs for aclidinium (COPD) and linaclotide (IBS).
* Global revenue and R&D spend are based on the fiscal year ending March 31, 2011, the latest data available at press time.

Back to first page

Page 20 of 21
Share this article:
You must be a registered member of MMM to post a comment.

Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

Upward Move: Jose Rivera

Upward Move: Jose Rivera

Jose Rivera. EVP, account director, Concentric